mFast‐SeqS ‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostat...
mFast‐SeqS ‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Multiple prognostic biomarkers, including circulating tumour cell (CTC) counts, exist in metastatic castration‐resistant prostate cancer (mCRPC) patients, but none of them have been implemented into daily clinical care. The modified fast aneuploidy screening test‐sequencing system (mFast‐SeqS), which yields a genome‐wide aneuploidy score, is able t...
Alternative Titles
Full title
mFast‐SeqS ‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_5586ded94d52426a8e1b34ae1e5d9078
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5586ded94d52426a8e1b34ae1e5d9078
Other Identifiers
ISSN
1574-7891
E-ISSN
1878-0261
DOI
10.1002/1878-0261.13449
